Search Result

Results for "

bloodstream

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Antibiotic (1) Antifolate (1) Aurora Kinase (2) Autophagy (2) Bacterial (6) Biochemical Assay Reagents (4) Clathrin (1) Dihydrofolate reductase (DHFR) (1) DNA/RNA Synthesis (1) Drug Intermediate (1) Environmental Pollutants (1) FGFR (2) GCGR (1) Glucocorticoid Receptor (1) Glycosyltransferase (1) Hexokinase (1) Influenza Virus (2) Interleukin Related (1) IPK Superfamily (1) Isotope-Labeled Compounds (2) Parasite (7) Phosphodiesterase (PDE) (1) Reference Standards (1) Ser/Thr Protease (1) Serpin (2) Thrombin (1) Transferrin Receptor (2) TREM receptor (1) Virus Protease (3)
By Research Areas:	Cancer (6) Cardiovascular Disease (3) Endocrinology (1) Infection (10) Inflammation/Immunology (5) Metabolic Disease (4)
Oligonucleotides:	siRNA drugs (2) siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12054

Hesperadin Maximum Cited Publications 12 Publications Verification	Aurora Kinase Autophagy Influenza Virus Parasite	Cancer
Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC₅₀ of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral .

HY-109519

Simethicone	Environmental Pollutants Biochemical Assay Reagents	Others Cancer
Simethicone is an orally active defoamer. Simethicone reduces the surface tension of air bubbles in the gastrointestinal tract, causing them to be expelled by vomiting, exhalation or absorption into the bloodstream. Simethicone has potential applications in flatulence and colic .

HY-171099

SC-919 LI-2124	IPK Superfamily	Cardiovascular Disease Endocrinology
SC-919 is an orally active IP6K inhibitor, with an IC₅₀ of < 5.2 nM against IP6K1, < 3.8 nM against IP6K2, and 0.65 nM against IP6K3. By inhibiting the activity of IP6K, SC-919 reduces intracellular IP7 levels, thereby suppressing XPR1-mediated cellular phosphate efflux. SC-919 increases intracellular phosphate and ATP levels while reducing phosphate entry into the bloodstream, thus decreasing plasma phosphate levels. SC-919 can be used in research related to chronic kidney disease and hyperphosphatemia .

HY-157536

SMT-738	Bacterial	Infection Inflammation/Immunology
SMT-738 is a bacterial bactericide. SMT-738 targets the small molecules responsible for lipoprotein transport in Enterobacteriaceae, causing abnormal lipoprotein localization and bacterial cell death. SMT-738 inhibits the growth of E. coli and K. pneumoniae. SMT-738 reduces bacterial loads in mouse models of urinary tract infection, bloodstream infection, and pulmonary infection caused by Enterobacterales. SMT-738 can be used in the research of Enterobacteriaceae infections, urinary tract infections, bloodstream infections, and pneumonia .

HY-108860

Oncaspar PEG-L-asparaginase; Pegasparaginase	FGFR Interleukin Related	Inflammation/Immunology
Oncaspar (PEG-L-asparaginase; Pegasparaginase), a pegylated form of native Escherichia coli-derived L-asparaginase, breaks down the amino acid asparagine that are circulating in the bloodstream. Oncaspar plays an important role in acute lymphoblastic leukemia (ALL) through asparagine hydrolysis and activation of the integrated stress response (ISR) pathway .

HY-139398

TBI-223 1 Publications Verification	Antibiotic Bacterial	Infection
TBI-223 is an orally active oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb). TBI-223 exhibits an IC₅₀ of 68 μg/mL for inhibiting mitochondrial protein synthesis (MPS) in HepG2 cells. TBI-223 is effective in three mouse models (bloodstream infection, skin infection, and bone infection) of methicillin-resistant staphylococcus aureus infection. TBI-223 can be used for the study of tuberculosis .

HY-125961

T3Inh-1	FGFR Glycosyltransferase	Cancer
T3Inh-1 is a potent and selective inhibitor of ppGalNAc-T3 (IC₅₀=7 μM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream) .

HY-P99770

Omodenbamab 514-G3	Bacterial	Infection
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a K_D value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .

HY-B0388R

Probucol (Standard) 2 Publications Verification DH-581 (Standard)	Reference Standards Virus Protease	Metabolic Disease
Probucol (Standard) is the analytical standard of Probucol. This product is intended for research and analytical applications. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.

HY-169728

SID 24785302	Hexokinase Parasite	Infection
SID 24785302 is a hexokinase inhibitor with antiparasitic activity. SID 24785302 exhibits activity against T. brucei and Leishmania. SID 24785302 can be used for the research of mitochondrial DNA disorders and parasitic infection .

HY-118643

Cimlanod 1 Publications Verification BMS-986231; CXL-1427	Drug Intermediate	Cardiovascular Disease
Cimlanod (BMS-986231) is a second-generation Nitroxyl (HNO) donor for heart failure. Cimlanod (BMS-986231) delivers HNO via pH-dependent chemical breakdown when exposed to the neutral pH environment of the bloodstream. Cimlanod (BMS-986231) possesses positive lusitropic and inotropic as well as vasodilatory effects. Cimlanod is the prodrug of CXL-1020 (HY-147384) .

HY-155530

PEX5-PEX14 PPI-IN-1	Bacterial	Infection
PEX5-PEX14 PPI-IN-1 (Compound 8) is a PEX14-PEX5 PPI inhibitor. PEX5-PEX14 PPI-IN-1 disrupts the PEX5-TbPEX14 PPI with a K_i of 53 μM. PEX5-PEX14 PPI-IN-1 inhibits the bloodstream form of T. b. brucei (EC₅₀: 5 μM) .

HY-177619A

Belcesiran sodium DCR-S1459 sodium	Serpin	Others
Belcesiran is an alpha 1 antitrypsin (A1AT) inhibitor that acts by allowing the liver to synthesise the A1AT protein and pass it into the bloodstream.

HY-177619

Belcesiran DCR-S1459	Serpin	Others
Belcesiran, a siRNA, is an alpha 1 antitrypsin (A1AT) inhibitor that acts by allowing the liver to synthesise the A1AT protein and pass it into the bloodstream.

HY-N16397

Anhydrofulvic acid	Bacterial	Infection
Anhydrofulvic acid is a polyketide with antibacterial activity (notably against MRSA, MIC=8 mg/mL). Anhydrofulvic acid is promising for research of Gram-positive infections (e.g., skin, bloodstream) .

HY-166975

Polysarcosine 100 pSar 100	Biochemical Assay Reagents	Others
Polysarcosine 100 (pSar 100) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 100 can be used in drug delivery research .

HY-P3621

Biotinyl-Glucagon (1-29), human, bovine, porcine	GCGR	Metabolic Disease
Biotinyl-Glucagon (1-29), human, bovine, porcine is a biotinylated glucagon. Glucagon is a peptide hormone, produced by α-cells of the pancreas, can increase concentration of glucose and fatty acids in the bloodstream .

HY-106983

GR 250495X	Glucocorticoid Receptor	Inflammation/Immunology
GR 250495X is an inhaled glucocorticoid receptor agonist. GR 250495X is designed as a antedrug, which takes effect locally in the lungs but is rapidly metabolized and inactivated in the bloodstream after entering the systemic circulation, thereby minimizing systemic side effects. GR 250495X can be used in asthma research .

HY-12054A

Hesperadin hydrochloride	Aurora Kinase Autophagy Influenza Virus Parasite	Cancer
Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin hydrochloride inhibits Aurora B with an IC₅₀ of 250 nM .

HY-P991029

Sutacimig HMB-001	Thrombin Ser/Thr Protease TREM receptor	Cardiovascular Disease
Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia .

HY-12610

Carbonic anhydrase inhibitor 27	Parasite	Cancer
Carbonic anhydrase inhibitor 27 (compund 5g) is an antitrypanosomal agent that reduces parasites in the bloodstream and improves survival of infected mice .

HY-B0388S1

Probucol-d6 DH-581-d₆	Isotope-Labeled Compounds Virus Protease	Metabolic Disease
Probucol-d₆ is deuterium labeled Probucol. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.

HY-B0388S

Probucol-13C3	Isotope-Labeled Compounds Virus Protease	Metabolic Disease
Probucol- ¹³C₃ is the ¹³C-labeled Probucol. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.

HY-166973

Polysarcosine 20 pSar 20	Biochemical Assay Reagents	Others
Polysarcosine 20 (pSar 20) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 20 can be used in drug delivery research .

HY-166974

Polysarcosine 150 pSar 150	Biochemical Assay Reagents	Others
Polysarcosine 150 (pSar 150) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 150 can be used in drug delivery research .

HY-149985

Antitrypanosomal agent 12	Parasite	Infection
Antitrypanosomal agent 12 is a C20-phenylthiourea with trypanocidal and cytotoxic activities. Antitrypanosomal agent 12 shows antitrypanosomal activity with 50% growth inhibition (GI₅₀) values of 0.22 μM. Antitrypanosomal agent 12 induces faster cell swelling in bloodstream-form trypanosomes than Salinomycin (HY-15597) .

HY-120241

Reticulol K 251-1	Phosphodiesterase (PDE)	Cancer
Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .

HY-NP0210

Rat Transferrin	Transferrin Receptor	Inflammation/Immunology
Rat Transferrin is a rat-derived protein. Transferrin is the transport of iron in the bloodstream. Transferrin can also act as a growth factor .

HY-NP0237

Cynomolgus Monkey transferrin	Transferrin Receptor	Inflammation/Immunology
Cynomolgus Monkey transferrin is a cynomolgus monkey-derived protein. Transferrin is the transport of iron in the bloodstream. Transferrin can also act as a growth factor .

HY-N19754

Cladospirone B	Parasite	Infection
Cladospirone B is a secondary metabolite of the endophytic fungus Lasiodiplodia theobromae. Cladospirone B exhibits trypanocidal activity, with a MIC of 17.8 µM against Trypanosoma brucei. Cladospirone B can be used in the research of African human trypanosomiasis (sleeping sickness) .

HY-183053

UCP1173	Bacterial Dihydrofolate reductase (DHFR) Antifolate	Infection
UCP1173, propargyl-linked antifolate, is an antibacterial agent. UCP1173 inhibits DHFR enzymes, with IC₅₀ values of 0.014 μM for DfrB, 0.19 μM for DfrG, 0.27 μM for DfrA, and 0.091 μM for DfrK. UCP1173 inhibits growth of Staphylococcus aureus clinical isolates carrying dfrA, dfrG, or dfrK resistance genes. UCP1173 can be used for the research of bacterial infections .

HY-125188

NEU-4438	Parasite DNA/RNA Synthesis AMPK Clathrin	Infection
NEU-4438 is an antimalarial agent. NEU-4438 inhibits DNA synthesis, reduces AMPK-γ, and increases Clathrin heavy chain. NEU-4438 exhibits antiparasitic activity against Trypanosoma brucei. NEU-4438 reduces trypanosome tissue burden in a chronic HAT mouse model .

Cat. No.	Product Name

HY-L028

CNS-Penetrant Compound Library	1,096 compounds
The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy. MCE offers a unique collection of 1,096 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

CNS-Penetrant Compound Library

1,096 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 1,096 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L919

MCE CNS BBB Lead-like Library	27,503 compounds
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

MCE CNS BBB Lead-like Library

27,503 compounds

With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

Cat. No.	Product Name	Type